Weston Gordon, MD
Vascular Neurology · Saint Louis, MONPI 1942654322
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,339 of the $5,186 with a category attached, or 64.4%. 15 manufacturers reported payments, led by Imperative Care, Inc at 53.0% of the total. Reporting peaked in 2024 at $2,031 and has fallen 50.1% since, to $1,013 in 2025.
Across 69 payments — averaging $75.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Imperative Care, Inc$3K
- Microvention, Inc.$1K
- Penumbra, Inc.$743
- Genentech, Inc.$77
- AbbVie$69
- Argenx US, Inc.$42
- plus $166 from 9 others
What the payments were for
- Travel & lodging$1,84736%
- Food & beverage$3,33964%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Imperative Care, Inc | 33 | $2,747 |
| Microvention, Inc. | 13 | $1,343 |
| Penumbra, Inc. | 8 | $743 |
| Genentech, Inc. | 1 | $77 |
| AbbVie | 3 | $69 |
| Argenx US, Inc. | 2 | $42 |
| Jazz Pharmaceuticals Inc. | 1 | $24 |
| TG Therapeutics, Inc. | 1 | $21 |
| Neurocrine Biosciences, Inc. | 1 | $21 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| Lilly USA, LLC | 1 | $18 |
| AstraZeneca | 1 | $17 |
| Tanabe Pharma America, Inc. | 1 | $16 |
| UCB, Inc. | 1 | $16 |
| Livanova USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few vascular neurology providers in Missourito place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other vascular neurology in Saint Louis
- Guillermo LinaresSaint Louis$11K
- Chike IlorahSaint Louis$5K
- Randall EdgellSaint Louis$687
- Adnan QureshiColumbia$60K
- Chizoba EzepueBridgeton$8K
- Camilo GomezColumbia$6K
- Amer AlshekhleeBridgeton$4K
- Brandi FrenchColumbia$3K
- Abdallah AmirehSaint Joseph$3K
- Firas Al ShakarchiKansas City$681
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.